160 related articles for article (PubMed ID: 14610241)
1. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.
Sauer JM; Long AJ; Ring B; Gillespie JS; Sanburn NP; DeSante KA; Petullo D; VandenBranden MR; Jensen CB; Wrighton SA; Smith BP; Read HA; Witcher JW
J Pharmacol Exp Ther; 2004 Feb; 308(2):410-8. PubMed ID: 14610241
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists.
Martínez C; Albet C; Agúndez JA; Herrero E; Carrillo JA; Márquez M; Benítez J; Ortiz JA
Clin Pharmacol Ther; 1999 Apr; 65(4):369-76. PubMed ID: 10223772
[TBL] [Abstract][Full Text] [Related]
3. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.
Ito K; Ogihara K; Kanamitsu S; Itoh T
Drug Metab Dispos; 2003 Jul; 31(7):945-54. PubMed ID: 12814973
[TBL] [Abstract][Full Text] [Related]
4. Identification of the human cytochromes P450 responsible for atomoxetine metabolism.
Ring BJ; Gillespie JS; Eckstein JA; Wrighton SA
Drug Metab Dispos; 2002 Mar; 30(3):319-23. PubMed ID: 11854152
[TBL] [Abstract][Full Text] [Related]
5. In vivo effects of interleukin-10 on human cytochrome P450 activity.
Gorski JC; Hall SD; Becker P; Affrime MB; Cutler DL; Haehner-Daniels B
Clin Pharmacol Ther; 2000 Jan; 67(1):32-43. PubMed ID: 10668851
[TBL] [Abstract][Full Text] [Related]
6. Effect of tadalafil on cytochrome P450 3A4-mediated clearance: studies in vitro and in vivo.
Ring BJ; Patterson BE; Mitchell MI; Vandenbranden M; Gillespie J; Bedding AW; Jewell H; Payne CD; Forgue ST; Eckstein J; Wrighton SA; Phillips DL
Clin Pharmacol Ther; 2005 Jan; 77(1):63-75. PubMed ID: 15637532
[TBL] [Abstract][Full Text] [Related]
7. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy.
Tracy TS; Venkataramanan R; Glover DD; Caritis SN;
Am J Obstet Gynecol; 2005 Feb; 192(2):633-9. PubMed ID: 15696014
[TBL] [Abstract][Full Text] [Related]
8. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
Chalon SA; Desager JP; Desante KA; Frye RF; Witcher J; Long AJ; Sauer JM; Golnez JL; Smith BP; Thomasson HR; Horsmans Y
Clin Pharmacol Ther; 2003 Mar; 73(3):178-91. PubMed ID: 12621383
[TBL] [Abstract][Full Text] [Related]
9. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism.
Sauer JM; Ponsler GD; Mattiuz EL; Long AJ; Witcher JW; Thomasson HR; Desante KA
Drug Metab Dispos; 2003 Jan; 31(1):98-107. PubMed ID: 12485958
[TBL] [Abstract][Full Text] [Related]
10. Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions.
Mao J; Mohutsky MA; Harrelson JP; Wrighton SA; Hall SD
Drug Metab Dispos; 2012 Apr; 40(4):706-16. PubMed ID: 22228749
[TBL] [Abstract][Full Text] [Related]
11. Polysaccharide peptides from Coriolus versicolor competitively inhibit model cytochrome P450 enzyme probe substrates metabolism in human liver microsomes.
Yeung JH; Or PM
Phytomedicine; 2012 Mar; 19(5):457-63. PubMed ID: 22305191
[TBL] [Abstract][Full Text] [Related]
12. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.
Gorski JC; Huang SM; Pinto A; Hamman MA; Hilligoss JK; Zaheer NA; Desai M; Miller M; Hall SD
Clin Pharmacol Ther; 2004 Jan; 75(1):89-100. PubMed ID: 14749695
[TBL] [Abstract][Full Text] [Related]
13. Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism.
Gibbs JP; Hyland R; Youdim K
Drug Metab Dispos; 2006 Sep; 34(9):1516-22. PubMed ID: 16763018
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes.
Zhu M; Zhao W; Jimenez H; Zhang D; Yeola S; Dai R; Vachharajani N; Mitroka J
Drug Metab Dispos; 2005 Apr; 33(4):500-7. PubMed ID: 15640381
[TBL] [Abstract][Full Text] [Related]
15. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude.
Venkatakrishnan K; Obach RS
Drug Metab Dispos; 2005 Jun; 33(6):845-52. PubMed ID: 15788540
[TBL] [Abstract][Full Text] [Related]
16. Effect of sodium ozagrel on the activity of rat CYP2D6.
Wu H; Yu W; Huang L; Wang J; Tang X; Yang W; Liu Y; Yu H; Zhu D
Eur J Pharmacol; 2007 Nov; 573(1-3):55-9. PubMed ID: 17651725
[TBL] [Abstract][Full Text] [Related]
17. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients.
LLerena A; de la Rubia A; Berecz R; Dorado P
Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614
[TBL] [Abstract][Full Text] [Related]
18. Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds.
Zientek M; Miller H; Smith D; Dunklee MB; Heinle L; Thurston A; Lee C; Hyland R; Fahmi O; Burdette D
J Pharmacol Toxicol Methods; 2008; 58(3):206-14. PubMed ID: 18634893
[TBL] [Abstract][Full Text] [Related]
19. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development.
Mori K; Hashimoto H; Takatsu H; Tsuda-Tsukimoto M; Kume T
Xenobiotica; 2009 Jun; 39(6):415-22. PubMed ID: 19480547
[TBL] [Abstract][Full Text] [Related]
20. Characterization of transgenic mouse strains using six human hepatic cytochrome P450 probe substrates.
Mankowski DC; Lawton MP; Ekins S
Xenobiotica; 2000 Aug; 30(8):745-54. PubMed ID: 11037108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
